Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2025 / December / Evaluation of AmblyoPlay in Pediatric Anisometropic Amblyopia
Research & Innovations Refractive Latest News

Evaluation of AmblyoPlay® in Pediatric Anisometropic Amblyopia

Six-month dichoptic therapy program led to significant gains across visual, binocular, and sensorimotor domains in school-aged children with anisometropic amblyopia

12/16/2025 4 min read

Share

Among  amblyopia's various subtypes, anisometropic amblyopia arises from unequal refractive error between the eyes, leading to chronic cortical suppression of the more ametropic eye, and impaired binocular development. Although traditional amblyopia management — most notably occlusion therapy and pharmacological penalization — has demonstrated efficacy in young children, these approaches are limited by age dependency, poor adherence, psychosocial burden, and a predominant focus on monocular visual acuity, rather than on binocular and sensorimotor function.

Emerging evidence suggests that amblyopia is not solely a visual acuity deficit, but is in fact a broader multisystem condition affecting binocular integration, oculomotor control, postural stability, and visuomotor coordination. Digital, gamified dichoptic therapies have therefore attracted growing interest as alternatives or adjuncts to conventional treatment, as they aim to restore binocular interaction while promoting engagement and adherence. AmblyoPlay® is a commercially available, app-based multimodal visual training platform built on dichoptic principles and designed to stimulate binocular vision through adaptive, game-based exercises. Prior to this study, however, no peer-reviewed clinical data had evaluated its therapeutic effects.

Study design and methods

This prospective, non-randomized, controlled pilot study was conducted to assess the impact of a six-month AmblyoPlay®-based visual rehabilitation program on visual, oculomotor, and sensorimotor outcomes in children with anisometropic amblyopia. Twenty-nine children aged 7 to 13 years were enrolled. Fourteen children with anisometropic amblyopia constituted the intervention group, while fifteen age- and sex-matched typically developing children with normal vision served as a control group.

Children in the amblyopia group completed a home-based AmblyoPlay® training program five days per week. Each session lasted approximately 30 minutes and was performed using red–green anaglyph glasses to enable dichoptic presentation. The software dynamically adjusted contrast, spatial frequency, and task difficulty based on real-time performance metrics, ensuring individualized and progressively challenging stimulation. All participants wore their full spectacle correction during training. Outcome measures were collected at baseline and at one, three, and six months for the amblyopia group, while controls were evaluated at baseline and at six months.

The primary outcome was best-corrected visual acuity (logMAR). Secondary outcomes included stereopsis, oculomotor function (saccades, smooth pursuit, and optokinetic responses measured via video-nystagmography), postural stability (computerized dynamic posturography), and motor proficiency (Bruininks–Oseretsky Test of Motor Proficiency, balance and upper-limb coordination subtests).

Key findings Visual acuity and binocular vision

Children undergoing AmblyoPlay® therapy exhibited statistically and clinically meaningful improvements in visual acuity in the amblyopic eye. Mean logMAR acuity improved from 0.23 at baseline to 0.08 at six months, corresponding to an approximate gain of 1.5 logMAR chart lines. Improvements were detectable as early as one month and continued progressively throughout the intervention, suggesting a cumulative therapeutic effect.

Stereopsis also improved markedly. Mean stereoacuity thresholds decreased from approximately 494 arcseconds at baseline to 61 arcseconds at six months, representing a substantial enhancement in binocular depth perception. In contrast, the control group demonstrated stable visual acuity and stereopsis over time, supporting the conclusion that observed changes were attributable to the intervention rather than maturation or test–retest effects.

Oculomotor function

The study demonstrated significant improvements in multiple oculomotor parameters in the amblyopia group. Saccadic latency decreased in both the amblyopic and fellow eyes, indicating faster visual processing and improved eye movement initiation. Smooth pursuit gain increased across all tested temporal frequencies, reflecting enhanced accuracy in tracking moving targets. Optokinetic gain also improved, suggesting better integration of motion signals across the visual field.

Importantly, these oculomotor changes were not observed in the control group, underscoring the specificity of the effect. Correlation analyses further revealed meaningful associations between improvements in visual acuity and oculomotor performance, supporting the hypothesis that dichoptic visual training facilitates broader recalibration of visual–motor pathways.

Motor proficiency and postural stability

Beyond visual outcomes, AmblyoPlay® therapy was associated with significant gains in sensorimotor function. Performance on the BOT-2 balance and upper-limb coordination subtests improved significantly over six months, indicating enhanced postural control and hand–eye coordination. While computerized dynamic posturography showed a positive trend toward improved balance, changes did not reach statistical significance, likely due to the limited sample size and relatively short intervention duration.

These findings align with growing evidence that impaired binocular vision in amblyopia can negatively affect motor development, and that targeted visual–motor training may promote functional gains extending beyond the visual system.

Clinical and scientific implications

The results of this pilot study suggest that AmblyoPlay® represents a promising multimodal digital intervention for pediatric anisometropic amblyopia. By combining dichoptic stimulation with adaptive, gamified tasks targeting visual, oculomotor, and visuomotor systems, the program appears capable of producing improvements not only in visual acuity but also in functional binocular vision and motor coordination.

Clinically, these findings support a paradigm shift away from treatments focused exclusively on monocular acuity toward integrative approaches that address amblyopia as a multisystem disorder. The home-based, engaging nature of the AmblyoPlay® platform may also mitigate common barriers associated with traditional therapies, including poor compliance and psychosocial burden.  

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: